✦ LIBER ✦

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

✍ Scribed by Li, Jun; Yao, Yunfeng; Jing, Juehua

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy of bevacizumab plus paclita

✍ Wang, Xuan; Huang, Chun; Li, Man; Gu, Yanjun; Cui, Yanfen; Li, Yan 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 395 KB

Bevacizumab plus paclitaxel versus bevac

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

Capecitabine plus paclitaxel versus epir

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB

5001 CIRG/TORI 010: first analysis of a

✍ M. Martin; S. Hurvitz; J. Kennedy; J. Forbes; H. Roché; T. Pinter; W. Eiermann; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

5016 Efficacy in patient subgroups in RI

✍ V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

RIBBON-2: A Randomized, Double-Blind, Pl

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB